Proteomic signatures reflect effects of semaglutide treatment for MASH.

ABSTRACT:

Background & aims

Proteomic technology has emerged as a non-invasive method for grading and staging metabolic dysfunction-associated steatohepatitis (MASH). The aims of this post hoc analysis of the STEP 1 and STEP 2 trials were to assess the distribution of SomaSignal-derived MASH components, evaluate the effect of semaglutide (2.4 mg and 1.0 mg) on these components, and test concordance with biopsy-based MASH histology from the phase IIb Sema-MASH trial.

Methods

Participants with overweight or obesity (STEP 1) and type 2 diabetes (STEP 2), who received once-weekly semaglutide or placebo for 68 weeks and had available biological samples, were included. In addition, participants with biopsy-confirmed MASH from the phase IIb Sema-MASH trial who received once-daily sema

SUBMITTER: Schattenberg JM 

PROVIDER: S-EPMC12447996 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature